Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.62 |
| ▸ | CA2 | P00918 | 3/20 | 0.62 |
| ▸ | CA7 | P43166 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA4 | P22748 | 1/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.47 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29435933 | 1.00 | CA1 (0.62) | CA1CA2CA7CA9CA12 | |
| SCHEMBL4654446 | 0.87 | RXRA (0.47) | CA1CA2CA7CA9CA12 | |
| SCHEMBL17039548 | 0.80 | KCNK3 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL2495060 | 0.80 | SMN1; SMN2 (0.45) | CA1CA2CA7CA9CA12 | |
| SCHEMBL6443536 | 0.80 | CA1 (0.54) | CA1CA2CA7CA9CA12 | |
| SCHEMBL6442063 | 0.80 | CA1 (0.54) | CA1CA2CA7CA9CA12 | |
| 1,2-Dimethoxybenzene SCHEMBL28757168 | 0.79 | CA1 (0.87) | CA1CA2CA7CA9CA12 | |
| 1,2-Dimethoxybenzene SCHEMBL29351917 | 0.79 | CA1 (1.00) | CA1CA2CA7CA9CA12 | |
| 1,2-Dimethoxybenzene SCHEMBL5308636 | 0.79 | CA1 (1.00) | CA1CA2CA7CA9CA12 | |
| 1,2-Dimethoxybenzene SCHEMBL105872 | 0.79 | CA1 (1.00) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090309070-A1 | COMPOSITIONS FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ORGANIC ELECTROLUMINESCENT DEVICE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-17 | — | — | US | claimed |
| US-12133453-B2 | Polymer, composition for organic electroluminescent element, organic electroluminescent element, organic EL display device, organic EL lighting, and manufacturing method for organic electroluminescent element | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-10-29 | — | — | US | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240107870-A1 | POLYMER, COMPOSITION FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC EL DISPLAY DEVICE, ORGANIC EL LIGHTING, AND MANUFACTURING METHOD FOR ORGANIC ELECTROLUMINESCENT ELEMENT | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-03-28 | — | — | US | disclosed |
| US-11943997-B2 | Polymer, composition for organic electroluminescent element, organic electroluminescent element, organic EL display device, organic EL lighting, and manufacturing method for organic electroluminescent element | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-03-26 | — | — | US | disclosed |
| CN-112955436-B | 6-oxo-1, 6-dihydropyridazine derivatives, preparation method and application thereof in medicines | 福建盛迪医药有限公司 | 2023-08-11 | — | — | CN | disclosed |
| WO-2022059725-A1 | POLYMER | 三菱ケミカル株式会社 | 2022-03-24 | — | — | WO | disclosed |
| US-11185514-B2 | Aqueous solution comprising a polyphenol | OPTERION HEALTH AG (CH) | 2021-11-30 | — | — | US | disclosed |
| EP-3907218-A1 | 6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2021-11-10 | — | — | EP | disclosed |
| US-11160766-B2 | Peritoneal therapeutic fluid | OPTERION HEALTH AG (CH) | 2021-11-02 | — | — | US | disclosed |
| US-7273879-B2 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-09-25 | — | — | US | disclosed |
| EP-1539744-A4 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARM INC (US) | 2007-06-06 | — | — | EP | disclosed |
| US-20060182993-A1 | COMPOSITIONS FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ORGANIC ELECTROLUMINESCENT DEVICE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2006-08-17 | — | — | US | disclosed |
| US-20060014962-A1 | Thiadiazole compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-01-19 | — | — | US | disclosed |
| US-20050215578-A1 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-09-29 | — | — | US | disclosed |
| EP-1550661-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-1539744-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1475374-A1 | THIADIAZOLE COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-11-10 | — | — | EP | disclosed |
| WO-2004007444-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-1998017660-A1 | PHENYL SPIROETHERCYCLOALKYL TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11160766-B2 | Peritoneal therapeutic fluid | FABP6, ALB, FABP2 | CA1 491/4885CA2 2279/4885CA7 855/4885 |
| US-11185514-B2 | Aqueous solution comprising a polyphenol | SORD, SI, AQP1 | CA1 1659/4885CA2 3012/4885CA7 455/4885 |
| US-20050215578-A1 | Thiadiazole compounds and use thereof | C5, C3AR1, TH | CA1 4786/4885CA2 4499/4885CA7 3031/4885 |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | CA1 2579/4885CA2 1239/4885CA7 1038/4885 |
| US-20060014962-A1 | Thiadiazole compound and use thereof | CBR3, TH, CYP2E1 | CA1 4504/4885CA2 3465/4885CA7 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.